English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

pMayo of 0 1 points and endoscopic Mayo subscore of 0 points at week 52. The time elapsed between the diagnosis and the first biological therapy was assessed in every patient, who was then categorized to groups according to the elapsed time (0 2 years, 2 5 years, 5 10 years etc). Data were collected from five Hungarian IBD centres. Results: The mean elapsed time between the diagnosis and the start of biological therapy was 7 years. 50.4% of patients started infliximab therapy within 5 years after diagnosis. After induction with infliximab 65.6% of the enrolled patients achieved remission and 34.4% achieved response. After oneyear treatment period, the remission and response rates remained 67.7% and 21.8%. 10.6% of patients showed loss of efficacy at one year infliximab therapy. 74.6% of subjects achieved clinical remission at week 14 and remained in remission at week 52. Complete mucosal healing was detected in 31.2% and deep remission in 13.9% of the patients at week 52. Response rates to infliximab therapy at one year were significantly lower compared to rates at week 14 (p = 0.029). The rate of response, remission and loss of efficacy did not depend on the elapsed time between the diagnosis and the start of biological therapy. Conclusions: Our results did not reveal an association between the remission rates and the elapsed time between the diagnosis and the first biological therapy in UC.

P322 The effects of anti TNF therapy on growth in Scottish children with IBD